Internship

Summer Internship Program: Packaging Development Engineer Intern

Posted on 4/3/2025

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

Compensation Overview

$21 - $46/hr

No H1B Sponsorship

Lexington, MA, USA

This is a hybrid position located in Lexington, MA.

Category
Process Engineering
Requirements
  • Current undergraduate or master's student pursuing a degree in Packaging Science or Packaging Engineering.
  • Experience or knowledge of pharmaceutical packaging design/process and packaging materials.
  • Technical and analytical skills for support of testing and process validations.
  • Coursework or experience in a regulated industry preferred.
Responsibilities
  • Will be a supporting team member for ongoing projects for packaging development activities in a cross-functional team environment for drug and combination products.
  • Provide support to test plans and protocols for verification of primary and secondary packaging, human factors studies, and manufacturing operations.
  • Will work with external vendors and test labs to support project work.
  • Will provide hands on support for concept testing in a lab environment.
  • Will also provide support and contribute to sustainable packaging initiatives.
Desired Qualifications
  • Must be currently enrolled in a degree program graduating December 2025 or later.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline aiming for multiple product launches through FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate continuously while ensuring that patient needs are prioritized and to contribute positively to public health and the environment.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's focus on personalized medicine can increase treatment efficacy and patient satisfaction.
  • Expansion in Southeast Asia offers opportunities for increased market presence and revenue growth.
  • Collaborations with tech companies can accelerate R&D processes and reduce costs.

What critics are saying

  • Data breach could lead to financial and reputational damage for Takeda.
  • Antitrust litigation with Meijer may result in financial penalties or business practice changes.
  • High financial commitments in partnerships could strain resources if outcomes are not achieved.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and R&D efforts.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 product launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

INACTIVE